Epilepsy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People of any background, male or female, aged 18 or older at the time they started cenobamate
- People diagnosed with epilepsy who have focal-onset seizures that were not controlled by 2 to 5 previous anti-seizure medications, and who then started treatment with cenobamate
- People who had at least 1 seizure per month in the 6 months before starting cenobamate
- People whose medical records include at least 6 months of health information before they started cenobamate
- People whose medical records include at least 12 months of health information after starting cenobamate, with no gap longer than 6 months between records
- People who have agreed to allow their personal data to be used in line with data protection regulations
Who may not be able to join:
- People for whom any approved anti-seizure medication used alongside cenobamate is medically contraindicated according to official prescribing guidelines
- People who began taking cenobamate through an Early Access Programme (a scheme allowing access to medicines before full approval)
- People with a progressive neurological disease, such as a degenerative brain or nervous system condition, or a brain tumour that is growing
- People with specific epilepsy syndromes such as Lennox-Gastaut Syndrome (LGS) or Dravet Syndrome
- People who are pregnant or breastfeeding
- People who are assessed as not being able to make independent decisions about their own participation
- People with current or recent substance or alcohol misuse or dependence (excluding caffeine and nicotine)
- People who have taken part in another clinical or interventional study in the 6 months before starting cenobamate
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +46 702528077
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Impact of cenobamate used as adjunctive therapy on epilepsy-related healthcare resources utilization (HCRU), stratified by early and later treatment lines.; Impact of cenobamate used as adjunctive therapy on epilepsy-related healthcare resources utilization (HCRU), stratified by early and later treatment lines.; Impact of cenobamate used as adjunctive therapy on epilepsy-related healthcare resources utilization (HCRU), stratified by early and later treatment lines; Impact of cenobamate used as adjunctive therapy on epilepsy-related healthcare resources utilization (HCRU), stratified by early a...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.